Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE study economic evaluation

Ininga R P, Dasbach E J, Allen S E, Carides G W, Myers E R

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by CRD

MeSH
Cost-Benefit Analysis; Humans; Papillomavirus Infections; Papillomavirus Vaccines

AccessionNumber
22008102142

Date bibliographic record published
15/07/2009